Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer

Endocrine-Related Cancer

Volumn 12, Issue 4, 2005, Pages 1051-1058

  Melisi, Davide ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Bianco, Roberto ^a   Veneziani, Bianca Maria ^a,c   Bianco, A Raffaele ^a,c   De Placido, Sabino ^a,c   Ciardiello, Fortunate ^b,c   Tortora, Giampaolo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Oncotech   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; GEFITINIB; ZOLEDRONIC ACID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EVALUATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEINS; PYRAZOLES; QUINAZOLINES; SIGNAL TRANSDUCTION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 29144521942     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01061     Document Type: Article

References (29)

1. Adami S 1997 Biphosphonate in prostate carcinoma. Cancer 80 1674-1679.
2. Blain SW, Scher HI, Cordon-Cardo C & Koff A 2003 p27 as a target for cancer therapeutics. Cancer Cell 3 111-115.
3. Buchanan FG, Wang D, Bargiacchi F & DuBois RN 2003 Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. Journal of Biological Chemistry 278 35451-35457.
4. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P et al. 2004 The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23 6900-6913.
5. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR & Shin DM 2004 Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical Cancer Research 10 5930-5939.
6. Chou TC & Talalay P 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22 27-55.
7. Ciardiello F & Tortora G 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research 7 2958-2970.
8. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR & Tortora G 1996 Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Journal of the National Cancer Institute (Bethesda) 88 1770-1776.
9. Ciardiello F, Bianco R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR & Tortora G 2004 Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clinical Cancer Research 10 784-793.
10. Green JR 2003 Antitumor effects of bisphosphonates. Cancer 97 840-847.
11. Gupta S, Srivastava M, Ahmad N, Bostwick DG & Mukhtar H 2000 Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 73-78.
12. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A et al. 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 21 4042-4057.
13. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D & Fidler IJ 2005 Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Research 65 3707-3715.
14. Lacerna L & Hohneker J 2003 Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Seminars in Oncology 30 150-160.
15. Masferrer JL, Koki A & Seibert K 1999 COX-2 inhibitors. A new class of antiangiogenic agents. Annals of the New York Academy of Sciences 889 84-86.
16. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T & Wada H 2005 Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 31-39.
17. Mendelsohn J & Baselga J 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology 21 2787-2789.
18. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D & Tarnawski AS 2002 Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine 8 289-293.
19. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP & Robertson FM 1997 Cyclooxygenase-2 gene expression in human breast cancer. International journal of Oncology 10 503-507.
20. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J & Frith JC 2000 Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 2961-2978.
21. Shao J, Lee SB, Guo H, Evers BM & Sheng H 2003 Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Research 63 5218-5223.
22. Sinensky M 2000 Recent advances in the study of prenylated proteins. Biochimica et Biophysica Acta 1484 93-106.
23. Smith WL, DeWitt DL & Garavito RM 2000 Cyclooxygenases: structural, cellular, and molecular biology. Annual Review of Biochemistry 69 145-182.
24. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR et al. 2003 Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. British Journal of Cancer 88 1971-1978.
25. Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, Pelicci PG & Ciardiello F 1997 The RI subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 14 923-928.
26. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR & Ciardiello F 2003 Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical Cancer Research 9 1566-1572.
27. Tortora G, Melisi D & Ciardiello F 2004 Angiogenesis: a target for cancer therapy. Current Pharmaceutical Design 10 11-26.
28. Turini ME & DuBois RN 2002 Cyclooxygenase-2: a therapeutic target. Annual Review of Medicine 53 35-57.
29. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J & Kerbel RS 2001 Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Research 61 5090-5101.